La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

BridgeBio Pharma Gestion

Gestion contrôle des critères 2/4

Le PDG BridgeBio Pharma's est Neil Kumar, nommé en Apr2015, a un mandat de 9.33 ans. La rémunération annuelle totale est $ 12.16M, composée du salaire de 6.1% et des bonus 93.9%, y compris les actions et options de la société. détient directement 3.67% des actions de la société, d'une valeur de € 152.01M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 4.6 ans.

Informations clés

Neil Kumar

Directeur général

US$12.2m

Rémunération totale

Pourcentage du salaire du PDG	6.1%
Durée du mandat du directeur général	9.5yrs
Propriété du PDG	3.7%
Durée moyenne d'occupation des postes de direction	5.3yrs
Durée moyenne du mandat des membres du conseil d'administration	4.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Neil Kumar a-t-elle évolué par rapport aux bénéfices de BridgeBio Pharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$454m
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

Rémunération vs marché: La rémunération totale de Neil ($USD 12.16M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 2.49M ).

Rémunération et revenus: La rémunération de Neil a augmenté alors que l'entreprise n'est pas rentable.

PDG

Neil Kumar (45 yo)

9.5yrs

Titularisation

US$12,158,626

Compensation

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He served as Pr...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Neil Kumar	Co-Founder	9.5yrs	US$12.16m	3.67% $ 158.7m
Charles Homcy	Co-Founder	no data	US$1.11m	0.65% $ 28.3m
Frank McCormick	Co-Founder	no data	US$1.74m	0.59% $ 25.3m
Brian Stephenson	CFO & Secretary	6yrs	US$6.65m	0.045% $ 2.0m
Richard Scheller	Chairman of Research & Development	5.8yrs	US$2.01m	pas de données
Thomas Trimarchi	President & COO	less than a year	pas de données	0.20% $ 8.7m
Uma Sinha	Chief Scientific Officer	8.5yrs	US$2.75m	pas de données
Grace Rauh	Vice President of Communications	no data	pas de données	pas de données
Eli Wallace	Chief Scientific Officer of Oncology	4.8yrs	pas de données	pas de données
Eric David	Chief Executive Officer of Gene Therapy	no data	pas de données	pas de données
Matthew Outten	Chief Commercial Officer	3.4yrs	pas de données	pas de données
Adora Ndu	Chief Regulatory Affairs Officer	2.8yrs	pas de données	pas de données

5.3yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2CL est chevronnée et expérimentée (ancienneté moyenne 5.1 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Neil Kumar	Co-Founder	9.5yrs	US$12.16m	3.67% $ 158.7m
Charles Homcy	Co-Founder	5.9yrs	US$1.11m	0.65% $ 28.3m
Frank McCormick	Co-Founder	less than a year	US$1.74m	0.59% $ 25.3m
Fred Hassan	Independent Director	3.2yrs	US$600.00k	0.010% $ 443.5k
Ronald Daniels	Independent Director	4.7yrs	US$600.00k	0.0055% $ 239.0k
Eric Aguiar	Independent Director	5.6yrs	US$600.00k	0% $ 0
Randal Scott	Independent Director	4.3yrs	US$600.00k	0.0048% $ 207.0k
Ali Satvat	Independent Director	8.6yrs	US$600.00k	0% $ 0
James Momtazee	Director	8.6yrs	US$600.00k	0.047% $ 2.0m
Jennifer Cook	Director	4.8yrs	US$600.00k	0.0038% $ 164.2k
Wen-Chaun Lo	Independent Director	4.3yrs	US$600.00k	0.13% $ 5.8m
Andrea Ellis	Independent Director	3.2yrs	US$600.00k	0.0064% $ 275.8k

4.8yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2CL sont considérés comme expérimentés (ancienneté moyenne 4.6 ans).

BridgeBio Pharma Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

Insider recently bought €75k worth of stock

Independent Director recently bought €264k worth of stock

BridgeBio Pharma, Inc. Announces Executive Changes

Recent updates

BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024

BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney

Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023)

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.92 loss in 1Q 2023)

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022)

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 21% undervalued

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Third quarter 2023 earnings released: US$1.08 loss per share (vs US$0.93 loss in 3Q 2022)

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022)

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.35 loss in 1Q 2022)

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)

Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

Third quarter 2022 earnings released: US$0.93 loss per share (vs US$1.06 loss in 3Q 2021)

BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib)

BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

Second quarter 2022 earnings released: US$0.067 loss per share (vs US$0.66 loss in 2Q 2021)

BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias

BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01

BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Insider recently bought €75k worth of stock

Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO).

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Independent Director recently bought €264k worth of stock

BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study

LianBio and BridgeBio Pharma, Inc. Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

Bridgebio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to Its Board of Directors

BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

QED Therapeutics and Partner Helsinn Group Announce FDA Approval of Truseltiq™ (infigratinib) for Patients with Cholangiocarcinoma

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

Forecast to breakeven in 2025

BridgeBio Pharma, Inc. (NasdaqGS:BBIO) announces an Equity Buyback for $150 million worth of its shares.

BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting

New 90-day high: €59.72

BridgeBio Pharma, Inc. and affiliate Origin Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A